Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers

Mechanisms of Ageing and Development

Volumn 127, Issue 2, 2006, Pages 129-132

  Parnetti, Lucilla ^a   Lanari, Alessia ^a   Silvestrelli, Giorgio ^a   Saggese, Emanuele ^a   Reboldi, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Amyloid 1 42; Alzheimer's disease; Cerebrospinal fluid; Mild cognitive impairment; Phosphorylated tau; Total tau

Indexed keywords

AMYLOID BETA PROTEIN; BETA AMYLOID PROTEIN[1-42]; BIOCHEMICAL MARKER; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NEUROPSYCHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; COGNITION DISORDERS; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; TAU PROTEINS;

EID: 31544449697     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mad.2005.09.022     Document Type: Conference Paper

References (24)

1. N. Andreasen, L. Minthon, E. Vanmechelen, H. Vanderstichele, P. Davidsson, B. Winblad, and K. Blennow Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment Neurosci. Lett. 273 1999 5 8
2. K. Blennow, and H. Hampel CSF markers for incipient Alzheimer's disease Lancet Neurol. 2 October 2003 605 613
3. K. Blennow, E. Vanmechelen, and H. Hampel CSF total tau, Aβ42 and phosphorylated tau protein as biomarkers for Alzheimer's disease Mol. Neurobiol. 24 2001 87 97
4. H. Braak, and E. Braak Staging of Alzheimer's disease-related neurofibrillary changes Neurobiol. Aging 16 1995 271 278
5. H. Braak, and E. Braak Evolution of neuronal changes in the course of Alzheimer's disease J. Neural. Trans. Suppl. 53 1998 127 140
6. K. Buerger, S.J. Teipel, R. Zinkowski, K. Blennow, H. Arai, R. Engel, K. Hofmann-Kiefer, C. McCulloch, U. Ptok, R. Heun, N. Andreasen, J. DeBernardis, D. Kerkman, H. Moeller, P. Davies, and H. Hampel CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects Neurology 59 2002 627 629
7. L. Davies, B. Wolska, C. Hilbich, G. Multhaup, R. Martins, G. Simms, K. Beyreuther, and C.L. Masters A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques Neurology 38 1988 1688 1693
8. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas among two or more correlated receiver operating characteristic curves: a non parametric approach Biometrics 44 1988 837 845
9. B. Dubois, and M.L. Albert Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurol. 3 2004 246 248
10. G.B. Frisoni, A. Padovani, and L.O. Wahlund The diagnosis of Alzheimer disease before it is Alzheimer dementia Arch. Neurol. 60 2003 1023
11. H. Hampel, A. Mitchell, K. Blennow, R.A. Frank, S. Brettschneider, L. Weller, and H.J. Moller Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity J. Neural. Trans. 111 2004 247 272
12. C. Hesse, L. Rosengren, N. Andreasen, P. Davidsson, H. Vanderstichele, E. Vanmechelen, and K. Blennow Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke Neurosci. Lett. 297 2001 187 190
13. C.L. Masters, G. Simms, N.A. Weinman, G. Multhaup, B.L. McDonald, and K. Beyreuther Amyloid plaque core protein in Alzheimer disease and Down syndrome Proc. Natl. Acad. Sci. U.S.A. 82 1985 4245 4249
14. I.G. McKeith, A.F. Fairbairn, R.H. Perry, and P. Thompson The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT) Br. J. Psychiatry 165 1994 324 332
15. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease Neurology 34 1984 939 944
16. M. Otto, J. Wiltfang, H. Tumani, I. Zerr, M. Lantsch, J. Kornhuber, T. Weber, H.A. Kretzschmar, and S. Poser Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease Neurosci. Lett. 225 1997 210 212
17. M.S. Parihar, and T. Hemnani Alzheimer's disease pathogenesis and therapeutic interventions J. Clin. Neurosci. 11 2004 456 467
18. R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E.G. Tangalos, and E. Kokmen Mild cognitive impairment: clinical characterization and outcome Arch. Neurol. 56 1999 303 308
19. J.L. Price, and J.C. Morris Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease Ann. Neurol. 45 1999 358 368
20. M. Riemenschneider, N. Lautenschlager, S. Wagenpfeil, J. Diehl, A. Drzezga, and A. Kurz Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment Arch. Neurol. 59 2002 1729 1734
21. M. Sjogren, H. Vanderstichele, H. Agren, O. Zachrisson, M. Edsbagge, C. Wikkelso, I. Skoog, A. Wallin, L.O. Wahlund, J. Marcusson, K. Nagga, N. Andreasen, P. Davidsson, E. Vanmechelen, and K. Blennow Tau and Aβ42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values Clin. Chem. 47 2001 1776 1781
22. D. Strozyk, K. Blennow, L.R. White, and L.J. Launer CSF Aβ42 levels correlate with amyloid-neuropathology in a population-based autopsy study Neurology 60 2003 652 656
23. The Lund and Manchester Groups Clinical and neuropathological criteria for frontotemporal dementia J. Neurol. Neurosurg. Psychiatry 57 1994 416 418
24. H. Zetterberg, L.O. Wahlund, and K. Blennow Cerebrospinal fluid markers for prediction of Alzheimer's disease Neurosci. Lett. 352 2003 67 69